{"role": "assistant", "content": null, "function_call": {"name": "get_risks", "arguments": "{\"risks\":[{\"Description\":\"High level of under-ascertainment of infections due to focus on testing in hospital settings rather than in the community.\",\"Impact\":\"Underestimation of infections could lead to inadequate control measures and increased transmission of the virus.\",\"Mitigation\":\"Increase testing in the community and develop antibody tests for representative population surveys.\",\"Technologies\":\"Antibody tests, testing kits for community use.\",\"People\":\"General population, healthcare workers.\",\"Owner\":\"Health authorities, government, public health agencies.\"},{\"Description\":\"Low percentage of individuals infected, with an attack rate on average of 4.9%.\",\"Impact\":\"The population is not close to herd immunity, leading to the potential for rapid spread of the virus if interventions are lifted.\",\"Mitigation\":\"Continue control measures, develop and implement vaccination strategies.\",\"Technologies\":\"Vaccines, continued monitoring and testing.\",\"People\":\"General population, healthcare workers, public health agencies.\",\"Owner\":\"Health authorities, government, pharmaceutical companies.\"},{\"Description\":\"Estimates imply that the populations in Europe are not close to herd immunity.\",\"Impact\":\"The rate of acquisition of herd immunity will slow down rapidly, and the virus will be able to spread rapidly if interventions are lifted.\",\"Mitigation\":\"Continue strict control measures, develop vaccination strategies, and validate estimates with newly developed antibody tests.\",\"Technologies\":\"Vaccines, antibody tests, population surveys.\",\"People\":\"General population, healthcare workers, public health agencies.\",\"Owner\":\"Health authorities, government, pharmaceutical companies.\"}]}"}}